Cernostics, Inc., a Pittsburgh-based company, will be attending the Digestive Disease Week Conference, May 6-9 in Chicago to share the latest data on their TissueCypher® test with Gastroentrologists, Surgeons and Physicians who treat patients with Barrett’s Esophagus, and are at risk of developing esophageal cancer.
“The TissueCypher® assay,” said Mike Hoerres, CEO of Cernostics, “provides gastroenterologists a rule-in test that identifies patients who need more aggressive treatment and surveillance because of their higher risk for esophageal cancer, and a rule-out test that identifies which patients aren’t likely to need aggressive treatment and surveillance for esophageal cancer.”
Barrett’s Esophagus is a precancerous condition predominantly seen in patients with longstanding acid reflux disease. In patients who suffer from Barrett’s Esophagus, the tissue that lines the esophagus—the food pipe that connects the mouth to the stomach—is replaced by abnormal, precancerous tissue. It’s estimated that as many as 10 million people in the United States suffer from Barrett’s Esophagus, and most don’t know they have it.
The TissueCypher® test aids pathologists’ interpretations of biopsies from upper gastrointestinal endoscopy procedures. The technology created by Cernostics, and now commercially available, uses digitally scanned images of a biopsy to measure and analyze cellular and molecular changes in the patient’s biopsy that indicate high risk of having or progressing to cancer.
Cernostics, Inc., is a leader in tissue-based diagnostic testing, providing assays with deeper tissue insights, better patient outcomes and lower cost of care. Mike Hoerres, CEO of Cernostics, headquartered in Pittsburgh, has spent more than 25 years commercializing new tools and technologies in the life-sciences and diagnostics industries. Before heading up Cernostics, he was Principal at Geisinger Ventures, the venture arm affiliated with Geisinger Health System, a leading, integrated healthcare delivery organization.
For more information, visit http://www.cernostics.com